20/20 Biolabs is trading 5.26% up at $0.24 in pre-market on November 5, versus the November 4 close of $0.23, amid biotech-sector strength; no clear company-specific catalyst was identified. - The biotech sector was reported up 2.08% pre-market amid optimism over Amgen earnings. - The company’s November 5 reminder covered its December 9 shareholder meeting and a proposed authorization for reverse splits between 1-for-2 and 1-for-250 to help regain Nasdaq’s $1.00 minimum-bid compliance; the release did not link it to the move.